scholarly journals Diabetes mellitus is associated with liver metastasis of colorectal cancer through production of biglycan-rich cancer stroma

Oncotarget ◽  
2020 ◽  
Vol 11 (31) ◽  
pp. 2982-2994 ◽  
Author(s):  
Rina Fujiwara-Tani ◽  
Takamitsu Sasaki ◽  
Kiyomu Fujii ◽  
Yi Luo ◽  
Takuya Mori ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Cancer Stroma

Increased Osteopontin-Positive Macrophage Expression in Colorectal Cancer Stroma with Synchronous Liver Metastasis

2010 ◽  
Vol 34 (8) ◽  
pp. 1930-1936 ◽  
Author(s):  
Motohiro Imano ◽  
Kiyokata Okuno ◽  
Tatsuki Itoh ◽  
Eizaburo Ishimaru ◽  
Takao Satou ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Synchronous Liver Metastasis ◽  
Cancer Stroma

scholarly journals Abstract 1067: Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis

2018 ◽  
Author(s):  
Tomohiro Murakami ◽  
Hirotoshi Kikuchi ◽  
Hisahito Ishimatsu ◽  
Sanshiro Kawata ◽  
Amane Hirotsu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Predictive Marker ◽  
Tenascin C ◽  
Cancer Stroma

scholarly journals Metformin Intake Suppresses The Degree of Liver Metastasis From Colorectal Cancer In Diabetic Patients But Does Not Improve Their Prognosis

2021 ◽  
Author(s):  
Akira Saito ◽  
Joji Kitayama ◽  
Hisanaga Horie ◽  
Koji Koinuma ◽  
Hideyuki Ohzawa ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Hepatic Metastases ◽  
Stage Iv ◽  
University Hospital ◽  
Diabetic Patients ◽  
Significant Difference ◽  
Patients With Diabetes

Abstract Background: Metformin reduces the risk of, and mortality from, colorectal cancer in patients with diabetes mellitus. However, the effect of metformin on patients with stage IV disease is unknown. In the present study we reviewed the clinical features and outcomes of patients with diabetes mellitus and stage IV colorectal cancer (M1, liver metastases) treated with or without metformin.Methods: The 202 patients with colorectal cancer and macroscopic liver metastasis who were treated in the Department of Surgery or Department of Clinical Oncology at Jichi Medical University Hospital from January 2006 through June 2019 were surveyed treatment of diabetes, clinical and pathological factor and prognosis of these patients. Results: We retrospectively examined the effect of metformin use on outcomes in 32 patients with liver metastases from colorectal cancer. Hepatic metastases were stage H1 in 8/8 patients taking metformin and stage H2-3 in 17/24 non-users. Of 22 patients who underwent colectomy, colorectal tumors were pT4 in 5 metformin users, and pT2-3 in 10/17 non-users. The mean survival of metformin users and non-users was equal (28.0 mo vs 29.3 mo, p>.05). No significant difference was detected when survival was compared between 6 metformin users and 19 non-users who received systemic chemotherapy. Conclusion: These results suggest that metformin has less potent anti-tumor effects in patients with advanced stage disease. Metformin for the treatment of patients with metastatic colorectal cancer requires further study.

scholarly journals Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis

2017 ◽  
Vol 117 (9) ◽  
pp. 1360-1370 ◽  
Author(s):  
Tomohiro Murakami ◽  
Hirotoshi Kikuchi ◽  
Hisato Ishimatsu ◽  
Ichirota Iino ◽  
Amane Hirotsu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Predictive Marker ◽  
Tenascin C ◽  
Cancer Stroma

scholarly journals The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis

2016 ◽  
Vol 27 ◽  
pp. iv41
Author(s):  
F. Passiglia ◽  
A. Galvano ◽  
S. Rizzo ◽  
A. Listì ◽  
N. Barraco ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Liver Metastasis ◽  
Surgical Resection ◽  
Meta Analysis ◽  
Prognostic Role ◽  
Colorectal Cancer Liver Metastasis

Stem cell gene Girdin: a potential early liver metastasis predictor of colorectal cancer

2012 ◽  
Vol 39 (9) ◽  
pp. 8717-8722 ◽  
Author(s):  
Chen Liu ◽  
Hongpeng Xue ◽  
Yixia Lu ◽  
Baorong Chi
Keyword(s):  
Colorectal Cancer ◽  
Stem Cell ◽  
Liver Metastasis ◽  
Cell Gene ◽  
Stem Cell Gene

scholarly journals Liver Immune Microenvironment and Metastasis from Colorectal Cancer-Pathogenesis and Therapeutic Perspectives

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2418
Author(s):  
Xuezhen Zeng ◽  
Simon E. Ward ◽  
Jingying Zhou ◽  
Alfred S. L. Cheng
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Cancer Patients ◽  
High Recurrence Rate ◽  
Immune Microenvironment ◽  
Liver Sinusoidal Endothelial Cells ◽  
Premetastatic Niche ◽  
Cancer Pathogenesis ◽  
Colorectal Cancer Patients ◽  
The Impact

A drastic difference exists between the 5-year survival rates of colorectal cancer patients with localized cancer and distal organ metastasis. The liver is the most favorable organ for cancer metastases from the colorectum. Beyond the liver-colon anatomic relationship, emerging evidence highlights the impact of liver immune microenvironment on colorectal liver metastasis. Prior to cancer cell dissemination, hepatocytes secrete multiple factors to recruit or activate immune cells and stromal cells in the liver to form a favorable premetastatic niche. The liver-resident cells including Kupffer cells, hepatic stellate cells, and liver-sinusoidal endothelial cells are co-opted by the recruited cells, such as myeloid-derived suppressor cells and tumor-associated macrophages, to establish an immunosuppressive liver microenvironment suitable for tumor cell colonization and outgrowth. Current treatments including radical surgery, systemic therapy, and localized therapy have only achieved good clinical outcomes in a minority of colorectal cancer patients with liver metastasis, which is further hampered by high recurrence rate. Better understanding of the mechanisms governing the metastasis-prone liver immune microenvironment should open new immuno-oncology avenues for liver metastasis intervention.

scholarly journals LncRNA MIR17HG promotes colorectal cancer liver metastasis by mediating a glycolysis-associated positive feedback circuit

Oncogene ◽  
2021 ◽  
Author(s):  
Senlin Zhao ◽  
Bingjie Guan ◽  
Yushuai Mi ◽  
Debing Shi ◽  
Ping Wei ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Positive Feedback ◽  
Feedback Loop ◽  
Metastatic Tumor ◽  
Feedback Circuit ◽  
Colorectal Cancer Liver Metastasis ◽  
Positive Feedback Circuit

AbstractGlycolysis plays a crucial role in reprogramming the metastatic tumor microenvironment. A series of lncRNAs have been identified to function as oncogenic molecules by regulating glycolysis. However, the roles of glycolysis-related lncRNAs in regulating colorectal cancer liver metastasis (CRLM) remain poorly understood. In the present study, the expression of the glycolysis-related lncRNA MIR17HG gradually increased from adjacent normal to CRC to the paired liver metastatic tissues, and high MIR17HG expression predicted poor survival, especially in patients with liver metastasis. Functionally, MIR17HG promoted glycolysis in CRC cells and enhanced their invasion and liver metastasis in vitro and in vivo. Mechanistically, MIR17HG functioned as a ceRNA to regulate HK1 expression by sponging miR-138-5p, resulting in glycolysis in CRC cells and leading to their invasion and liver metastasis. More interestingly, lactate accumulated via glycolysis activated the p38/Elk-1 signaling pathway to promote the transcriptional expression of MIR17HG in CRC cells, forming a positive feedback loop, which eventually resulted in persistent glycolysis and the invasion and liver metastasis of CRC cells. In conclusion, the present study indicates that the lactate-responsive lncRNA MIR17HG, acting as a ceRNA, promotes CRLM through a glycolysis-mediated positive feedback circuit and might be a novel biomarker and therapeutic target for CRLM.

scholarly journals Targeting BMI-1-mediated epithelial–mesenchymal transition to inhibit colorectal cancer liver metastasis

2020 ◽  
Author(s):  
Zhiyao Xu ◽  
Zhuha Zhou ◽  
Jing Zhang ◽  
Feichao Xuan ◽  
Mengjing Fan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Epithelial Mesenchymal Transition ◽  
Mesenchymal Transition ◽  
Colorectal Cancer Liver Metastasis
Sign in / Sign up

Export Citation Format

Share Document